Reuters logo
BRIEF-Dicerna files clinical trial application for DCR-PHXC for phase 1 study in hyperoxaluria
October 16, 2017 / 12:07 PM / a month ago

BRIEF-Dicerna files clinical trial application for DCR-PHXC for phase 1 study in hyperoxaluria

Oct 16 (Reuters) - Dicerna Pharmaceuticals Inc:

* Dicerna files clinical trial application for DCR-PHXC, the company’s most advanced GalXC™ product candidate, for phase 1 study in primary hyperoxaluria (ph)

* Dicerna Pharmaceuticals Inc - ‍company expects to initiate clinical dosing in Q1 2018​

* Dicerna Pharmaceuticals Inc - ‍company plans to submit additional CTAS in other European countries later this year​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below